The Office of Technology Transfer is responsible for intellectual property (IP) protection, development and commercialization, including for the six internationally recognized professional schools at UM - medicine, dentistry, nursing, pharmacy, social work, and law. We are committed to protecting and translating the discoveries of our researchers into commercial products to benefit society and the University. For additional information contact us: ott@umaryland.edu.
Events & News  One day session excites entrepreneurs (PDF, 3.2 Mb). (5/11/12)
Analytical Informatics, Inc announced an exclusive agreement with UM to commercialize innovative clinical informatics software developed at the University of Maryland School of Medicine, Department of Diagnostic Radiology and Nuclear Medicine. This new agreement will allow Analytical Informatics, Inc to commercialize many of the world-renowned clinical analytics tools the department has become so well known for. "We are very excited by this partnership, and by the opportunity to provide our customers with the innovative software tools developed at the University of Maryland" said Chris Meenan, CEO of Analytical Informatics. (5/1/12) School of Dentistry Invents Dental Fillings That Kill Bacteria and Remineralize the Tooth FDA Accepts PaxVax's IND for Single-Dose Oral Cholera Vaccine: Myron M. Levine M.D., Director of the Center for Vaccine Development at the University of Maryland School of Medicine and Albert B. Sabin Gold Medal winner, co-inventor of the vaccine now licensed to PaxVax..more..  University of Maryland Ventures, a new joint effort between the University of Maryland’s two biggest campuses, will soon create groups to help standardize the schools’ product licensing and technology transfer initiatives. More...Groundbreaking Research led by Dr. Angela Brodie Featured in New Clinical Trial to Treat Triple-Negative Breast Cancer Vaccine to Stop Rapidly Spreading GI Disease Shares Top Prize at Investor Conference Cephalon Signs Option Agreement to Acquire Assets from Alba Therapeutics Promising Compound in Stage II Clinical Trial for the Treatment of Celiac Disease | 
